Additionally, CYP1A1, a key Phase I DME, has previously been linked to increased breast cancer risk, while high CYP26B1 has been associated with poor prognosis in colorectal cancer [55,56,57]. This evidence concerns the gene CYP26B1 and breast carcinoma.